Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Management of patients with ocular manifestations in vesiculobullous disorders affecting the mouth

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Patients with burning mouth syndrome (BMS) often represent a clinical challenge as available agents for symptomatic treatment are few and often ineffective. The aim was to evaluate the effect of a bupivacaine lozenge on oral mucosal pain, xerostomia and taste alterations in patients with BMS.

METHODS: Eighteen 18 patients (4 men and 14 women) aged 39-71 years with BMS were included in this randomized, double-blinded, placebo-controlled, cross-over trial. Lozenges (containing bupivacaine or placebo) were administrated three times a day for two weeks for two separate treatment periods. Assessment of oral mucosal pain, xerostomia and taste alterations was performed in a patient diary on a visual analogue scale (ranging from 0-100 mm) before and after the lozenge was dissolved.

RESULTS: The bupivacaine lozenge significantly reduced the burning oral pain (p<0.001), increased the sense of taste disturbances (p<0.001), and had no impact on xerostomia, when adjusted for the treatment period.

CONCLUSIONS: Our results indicate that the bupivacaine lozenge offers a novel therapeutic modality to patients with BMS, although without alleviating effect on the associated symptoms, taste alterations and xerostomia. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalOral Diseases
Volume22
Issue number2
Pages (from-to)123-131
ISSN1354-523X
DOIs
Publication statusPublished - Mar 2016

ID: 45832675